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The Antarctic bacterium Pseudoalteromonas haloplanktis encodes for a c-class carbonic anhydrase (CA, EC
4.2.1.1), which was cloned, purified and characterized. The enzyme (PhaCAc) has a good catalytic activity
for the physiologic reaction of CO2 hydration to bicarbonate and protons, with a kcat of 1.4  105 s1 and a
kcat/Km of 1.9  106 M1  s1. A series of sulfonamides and a sulfamate were investigated as inhibitors of
the new enzyme. Methazolamide and indisulam showed the best inhibitory properties (KIs of
86.7–94.7 nM). This contribution shed new light on c-CAs inhibition profiles with a relevant class
of pharmacologic agents.
 2015 Elsevier Ltd. All rights reserved.Marine psychrophiles act as processors of the polar marine pri- environmental temperature in order to accommodate the sub-
mary productivity constituting the base for the entire polar food
web and, ultimately, feeding krill, fish, whales, penguins, and
seabirds.1,2 They play, in fact, a significant role in the so called ‘sub-
stance turnover’. Moreover, a feature common to all psychrophiles
are their remarkable ability to thrive under extremely cold and
salty conditions.3 Cold-adapted organisms have developed a num-
ber of adjustments at the molecular level to maintain metabolic
functions at low temperatures, such as the production of enzymes,
note as ‘cold-enzyme’.4–11 These enzymes are characterized by a
specific activity at low and moderate temperatures higher than
their mesophilic counterparts over a temperature range roughly
covering 0–30 C and by a relative instability.6,7,11–13 Probably, in
the case of psychrophilic microorganisms the selective pressure
is essentially exerted towards the specific activity and not towards
stability factors as happens in mesophilic or in thermophilic
enzymes. The molecular structure of a ‘cold-enzyme’ is primarily
characterized by an adequate plasticity of the molecule at thestrates with a minimum of energy expenditure.14 ‘Cold-enzymes’
naturally achieved a good compromise between activity and stabil-
ity. There is a continuum in the adaptation of a protein to its envi-
ronment.4–11,13,15–22 In fact, all known structural factors and weak
interactions involved in protein stability are either reduced in
number or modified in psychrophilic enzymes in order to increase
their flexibility; but the same structural factors are also implicate
for increasing the stability of the thermophilic proteins.23–29
Carbonic anhydrases (CAs; EC 4.2.1.1) are metalloenzymes that
catalyze CO2 hydration to bicarbonate and protons.4,5,30–38 These
enzymes are involved in a multitude of physiologic processes in
organisms all over the phylogenetic tree, with six genetically
distinct CA classes known to date: the a-, b-, c-, d-, f- and
g-CAs.26,39–50 Their biochemical features are known in detail for
at least four classes, together with their distribution and role in
various organisms.32,33,41,48–62 Inhibition and activation studies of
many such enzymes from vertebrates, protozoa, fungi and bacteria
have shown that they are drug targets for obtaining pharmacolog-
ical agents of the diuretic, antiglaucoma, antiobesity, antiepileptic,
anticancer or anti-infective type.55–58,60 Many such enzymes also
possess biotechnologic applications for biomimetic CO2 capture
processes.55–60 The cloning and characterization of many other
Figure 1. Multialignment performed with the program Clustal of the c-CAs from different microorganisms. The metal ion ligands (His81, His117 and His122) are indicated in
bold; the catalytically relevant residues of CAM (Asn73, Gln75 and Asn202), which participate in a network of hydrogen bonds with the catalytic water molecule, are boxed;
the CAM acidic loop residues containing the proton shuttle residues Glu84 is missing in the other c-CAs (CMA numbering system).
Table 1
Kinetic parameters for the CO2 hydration reaction catalysed by the human cytosolic
isozymes hCA I and II (a-class CAs) at 20 C and pH 7.5 in 10 mM HEPES buffer and
20 mM Na2SO4, the cyanobacterial b-CA from Coleofasciculus chthonoplastes, and the
c-CAs CAM (Methanosarcina thermophila), PgiCA (Porphyromonas gingivalis) and
NcoCA (Nostoc commune) measured at 20 C, pH 8.3 in 20 mM TRIS buffer and
20 mM NaClO4.
Enzyme Activity
level
Class kcat (s1) kcat/Km
(M1  s1)
KI
(acetazolamide)
(nM)
hCA I Moderate a 2.0  105 5.0  107 250
hCA II Very high a 1.4  106 1.5  108 12
CahB1 Low b 2.4  105 6.3  107 76
CAM Low c 6.1  104 8.7  105 63
PgiCA Moderate c 4.1  105 5.4  107 324
NcoCA High c 9.5  105 8.3  107 75.8
PhaCAc Medium–
low
c 1.4  105 1.9  106 403
Inhibition data with the clinically used sulfonamide acetazolamide (5-acetamido-
1,3,4-thiadiazole-2-sulfonamide) are also provided.
D. Vullo et al. / Bioorg. Med. Chem. Lett. 25 (2015) 3550–3555 3551such enzymes will probably lead to the discovery of other CA fam-
ilies as well as enzymes with potentially important technologic
applications.
CAs have been thoroughly investigated in mesophilic bacteria,
but a limited number of studies are available on CAs from psy-
chrophilic bacteria.5,23,25–30,34,36–38,42,44,46–50 In the present paper,
we describe the cloning, expression and purification of a c-CA
identified in the genome of Pseudoalteromonas haloplanktis (for-
merly Alteromonas haloplanktis), which is an obligate aerobic
gram-negative rod-like bacterium that was isolated from seawater
sampled along the Antarctic ice shelf. This species thrives perma-
nently in seawater at temperature ranging between +2 C and
+4 C, being able to survive in frozen conditions for a long period,
when entrapped in the winter ice pack.
The analysis of genomic DNA from the aforementioned psy-
chrophilic bacteria revealed that it encodes for CAs belonging to
the b- and c-classes. Here we report the cloning, purification and
kinetic characterization of the recombinant c-CA from P. haloplank-
tis and its inhibition profile with sulfonamides and their bioisos-
teres, such as the sulfamates. The new Antarctic c-CA was named
PhaCA. These studies are relevant at the level of the molecular
structure because they allows the comprehension of the adaptative
traits of the psychrophilic enzymes which have an unique goal: to
improve the catalytic efficiency at low temperatures and possibly
to gain conformational flexibility.
The P. haloplanktis PhaCAc gene encodes a 177 amino acid
polypeptide chain, which displays some identity with other such
enzymes cloned and characterized recently, such as the c-CA
(NcoCA) from the Antarctic cyanobacterium Nostoc commune
(37.3% identity; 69.0% similar); the mesophilic c-CA (PgiCA) iden-
tified in the genome of the anaerobic bacterium Porphyromonasgingivalis (41.7% identity, 78.5% similar); as well as with the proto-
typical c-CAs CAMH and CAM from the archaeon Methanosarcina
thermophila.61,62 Its alignment with the sequence of other c-CAs
(Fig. 1) shows that the metal ion ligands (His81, His117 and
His122) are conserved in all these enzymes, as well as the catalyt-
ically relevant residues Asn73, Gln75 and Asn202 (first evidenced
in CAM),61 which participate in a network of hydrogen bonds with
the catalytic water molecule. However the CAM acidic loop resi-
dues containing the presumed proton shuttle residue Glu84 is
missing in the other c-CAs investigated here (the CAM numbering
system is used throughout this paper).
3552 D. Vullo et al. / Bioorg. Med. Chem. Lett. 25 (2015) 3550–3555Indeed, as observed from data of Table 1, PhaCAc shows a sig-
nificant catalytic activity for the CO2 hydration reaction, similar
to other c-CAs investigated earlier such as CAM, PgiCA and
NcoCA.57,58,23,31,60 The kinetic parameters for the PhaCAc-cat-
alyzed CO2 hydration to bicarbonate and protons, were: kcat of
1.4  105 s1 and a kcat/Km of 1.9  106 M1  s1. This activity is
inhibited by the sulfonamide CA inhibitor (CAI) acetazolamide,
with a KI of 403 nM, in the same range as the c-CA PgiCA from P.
gingivalis or the human slow isoform hCA I (Table 1).
A phylogenetic tree was build for understanding the evolution-
ary relationship of the new enzymewith other c-CAs present in the
genomes of other organisms such as archaea and bacteria, but alsoSO2NH2
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yet investigated in detail or cloned, although they are present in
one of the most investigated organisms in molecular biology or
in a human pathogen provoking rather diffuse disease.
We investigated the susceptibility of PhaCAc to inhibition with
the main class of CA inhibitors (CAIs), the sulfonamides and their
isosteres (sulfamates).55–60 A panel of 40 such derivatives were
included in this study. Derivatives 1–24 and AAZ-HCT are either
simple aromatic/heterocyclic sulfonamides widely used as build-
ing blocks for obtaining new families of such pharmacological
agents,55–60 or they are clinically used agents, among whichacetazolamide AAZ, methazolamide MZA, ethoxzolamide EZA
and dichlorophenamide DCP, are the classical, systemically acting
antiglaucoma CA inhibitors (CAIs). Dorzolamide DZA and brinzo-
lamide BRZ are topically-acting antiglaucoma agents, benzolamide
BZA is an orphan drug belonging to this class of pharmacological
agents, whereas topiramate TPM, zonisamide ZNS and sulthiame
SLT are widely used antiepileptic drugs. Sulpiride SLP and indisu-
lam IND were also shown by our group to belong to this class of
pharmacological agents, together with the COX2 ‘selective’ inhibi-
tors celecoxib CLX and valdecoxib VLX. Saccharin and the diuretic
hydrochlorothiazide HCT are also known to act as CAIs. Inhibition
Table 2
Inhibition of human isoforms hCA I and hCA II, of the bacterial enzymes from
Methanosarcina thermophila (CAM) and Porphyromonas gingivalis (PgiCA)as well as the
cyanobacterial one from Nostoc commune (NcoCA) with sulfonamides 1–24 and the
clinically used drugs AAZ–HCT, by a CO2 hydrase, stopped-flow assay
Inhibitor/enzyme class KI* (nM)
hCA IIa
a
CAMb
c
PgiCAc
c
NcoCAd
c
PhaCAc
c
1 300 nt 4220 492 5460
2 240 250 893 488 9210
3 8 170 >100,000 683 >100,000
4 320 nt 945 785 >100,000
5 170 350 3600 825 >100,000
6 160 270 3840 742 6150
7 60 970 680 20,600 >100,000
8 110 140 662 23,750 >100,000
9 40 1720 201 872 7460
10 54 nt 218 2810 8450
11 63 830 711 632 8980
12 75 120 1040 269 8465
13 60 nt 510 84.7 6310
14 19 nt 595 480 6100
15 80 nt 326 7570 8760
16 94 nt 223 4034 9150
17 125 nt 178 777 >100,000
18 46 nt 560 74.6 8730
19 33 nt 685 78.3 5400
20 2 nt 1450 66.7 7690
21 11 nt 3540 402 8090
22 46 nt 4100 553 8465
23 33 180 4650 74.5 9290
24 30 nt 3400 40.3 8885
AAZ 12 63 324 75.8 403
MZA 14 140 343 191 94.7
EZA 8 200 613 264 679
DCP 38 190 1035 345 2465
DZA 9 410 685 67.4 831
BRZ 3 nt 722 81.3 735
BZA 9 nt 741 48.5 24,600
TPM 10 1020 >100,000 65.7 877
ZNS 35 nt 157 85.6 490
SLP 40 nt 418 60.5 >100,000
IND 15 nt 131 92.3 86.7
VLX 43 130 755 53.1 735
CLX 21 140 169 87.6 761
SLT 9 nt 424 82.4 898
SAC 5959 nt 273 408 867
HCT 290 nt 380 58.7 790
nt = not tested.
* Errors in the range of 5–10% of the shown data, from 3 different assays.
a Human recombinant isozymes, stopped flow CO2 hydrase assay method, from
Ref. 17.
b Recombinant protozoan enzyme, stopped flow CO2 hydrase assay method, from
Ref. [59].
c Recombinant bacterial enzyme, from Ref. [30].
d Recombinant bacterial enzyme, this work.
Figure 2. Phylogenetic trees of the c-CA and a-CA amino acid sequences from
different species. The tree was constructed using the program PhyML 3.0. Legend:
PhaCAgamma, Pseudoalteromonas haloplanktis (Accession number:
WP_016710385.1); ReuCAgamma, Ralstonia eutropha (Accession number:
YP_725701.1); bSuCAgamma, Brucella suis (Accession number: NP_698263.1);
BpsCAgamma, Burkholderia pseudomalle (Accession number: YP_108862.1);
SspCAgamma, Sulfurihydrogenibium yellowstonense (Accession number:
WP_007547159.1); SazCAgamma, Sulfurihydrogenibium azorense (Accession num-
ber: WP_012674376.1); PgiCAgamma, Porphyromonas gingivalis (Accession num-
ber: WP_012457873.1); EcoCAgamma, Escherichia coli (Accession number:
CDL59494); VchCAgamma, Vibrio cholerae; CAMgamma and CAMHgamma,
Methanosarcina thermophila (Accession numbers: P40881.1 for CAMgamma and
ACQ57353.1 for CAMHgamma); NcoCAgamma, Nostoc commune (Accession num-
ber: YP_007048658.1); HumCAIIalpha, Homo sapiens (Accession number:
AAH11949.1); HumaCAIalpha, Homo sapiens (Accession number: NP_001729.1);
SspCAalpha, Sulfurihydrogenibium yellowstonense, (Accession number:
WP_012459296.1); HplyCAalpha, Helicobacter pylori (Accession number:
WP_010882609.1); SsalCAalpha, Streptococcus salivarius, (Accession number:
WP_002888224.1); NgoCAalpha, Neisseria gonorrhea (Accession number:
WP_003688976.1).
3554 D. Vullo et al. / Bioorg. Med. Chem. Lett. 25 (2015) 3550–3555data of the human (h), possibly off target isoforms hCA I and II, and
the only other c-CAs investigated in detail so far, CAM, PgiCA
and NcoCA, are also presented in Table 2, for comparison reasons.
The following structure-activity relationship (SAR) data can be
observed for the inhibition of NcoCA with this panel of
sulfonamides/sulfamates:
(i) A number of sulfonamides, among which 3–5, 7, 8, 17 and
SLP were ineffective PhaCAc inhibitors up to concentrations
of 100 lM, They include simple benzenesulfonamides sub-
stituted in the 3, 4 or 3,4-positions with sulfamoyl, methyl,
aminomethyl, hydroxyethyl or halogeno and amino moi-
eties. Sulpiride is also a benzenesulfonamide incorporating
however a more complex scaffold.
(ii) The largest majority of the investigated derivatives were
weak, micromolar CAIs against PhaCAc, with inhibition con-
stants in the range of 2465–24,600 nM (Table 2. The com-
pounds in this category include 1, 2, 6, 9–16, 18–24, DCP
and BZA. It is interesting to note that these weak inhibitors
incorporate a variety of aromatic/heterocyclic sulfonamide
scaffolds, belonging to heterogeneous classes of compounds.
Furthermore, many of them show much better inhibitory
effects against a- or other c-CAs shown in Table 2 (e.g.; com-
pare 12, 18 and 19 against the various CAs from the Table).
(iii) A few of the clinically used derivatives were more effective
PhaCAc inhibitors, with KIs ranging between 403 and 898
nM. They include AAZ, EZA, DZA, BRZ, TPM, ZNS, VLX,
CLX, SLT, SAC and HCT. Although the activity of these
compound as CAIs is not excellent, their large structural
variability shows that probably this c-CA, relatively not
highly sensitive to sulfonamide inhibitors, may be betterinhibited by some compounds belonging to this class. And
indeed, this seems to be the case for the last two compounds
discussed shortly.
(iv) Two inhibitors with efficacy <100 nM were detected in this
study, MZA, with a KI of 94.7 nM, and IND with a KI of
86.7 nM. These compounds are rather different structurally
between them, and still they show an effective inhibition
profile of the enzyme. It should be also noted that the struc-
tural differences between MZA and AAZ is minimal (an extra
CH2 group in MZA) and still the two compounds differ by a
factor of 4.25 as PhaCAc inhibitors (Table 2). Furthermore,
the deacetylated MZA derivative (compound 14) is
64.4 times a weaker inhibitor compared to MZA. All these
data suggest that small differences in the inhibitor scaffold
lead to dramatic differences of activity.
D. Vullo et al. / Bioorg. Med. Chem. Lett. 25 (2015) 3550–3555 3555In conclusion, we investigated the Antarctic bacterium P. halo-
planktis, which encodes for a c-class CA. The enzyme (PhaCAc)
was cloned, purified and characterized in detail. It shows a good
catalytic activity for the physiologic reaction of CO2 hydration to
bicarbonate and protons, with a kcat of 1.4  105 s1 and a kcat/Km
of 1.9  106 M1  s1. A series of sulfonamides and a sulfamate
were also investigated as inhibitors of PhaCAc, considering that
this is the main class of compounds possessing high affinity for
CAs. Methazolamide and indisulam showed the best inhibitory
properties (KIs of 86.7–94.7 nM) followed by acetazolamide,
zonisamide, ethoxzolamide, brinzolamide and valdecoxib, which
showed inhibition constants in the range of 403–735 nM. Other
aromatic/heterocyclic sulfonamides and topiramate were ineffec-
tive, micromolar PhaCAc inhibitors. As the c-CAs seem to be the
most ancient class of such enzymes and they were poorly investi-
gated up until now, this contribution may shed some light on their
inhibition profiles with a relevant class of pharmacologic agents.
Moreover, the inhibition study curried out on this Antarctic CA
represents an excellent scientific tentative for searching and
designing selective drug for structurally very similar CA classes.
In fact, the identification of such class-selective compounds may
led to novel drugs with less side effects compared to those used
in a wide range of diseases.
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